Aminoglycosides
| Drug | Dosage | Remarks |
|---|---|---|
| Amikacin | 15 mg/kg/day IM/IV divided 8-12 hourly x 7-10 days Max dose: 1.5 g/day |
Adverse Reactions
|
| Gentamicin | 3-5 mg/kg/day IM/IV divided 8-12 hourly |
Antibacterial Combination
| Drug | Dosage | Remarks |
|---|---|---|
| Co-trimoxazole (Sulfamethoxazole [SMX] and Trimethoprim [TM]) |
800 mg SMX/160 mg TM PO 12 hourly | Adverse Reactions
|
Cephalosporins
| Drug | Dosage | Remarks |
|---|---|---|
| First Generation |
Adverse Reactions
|
|
| Cefaclor | 250-500 mg PO 8 hourly | |
| Cefadroxil | 1 g PO 24 hourly or divided 12 hourly | |
| Cefalexin (Cephalexin) | 250 mg PO 6 hourly or 500 mg PO 12 hourly | |
| Cefazolin | 1 g IV/IM 6 hourly | |
| Cefradine (Cephradine) | 1-2 g/day divided 6-12 hourly or 2-4 g/day IV/IM divided 6 hourly |
|
| Second Generation | ||
| Cefmetazole | 500 mg-1 g IV 12 hourly | |
| Cefotiam | 200-400 mg PO 12 hourly | |
| Cefoxitin | 1-2 g IV/IM 6-8 hourly | |
| Cefprozil | 250 mg PO 12 hourly or 500 mg PO 12-24 hourly | |
| Cefuroxime | 250-500 mg PO 12 hourly or 750 mg-1.5 g IV/IM 6-8 hourly | |
| Third Generation | ||
| Cefdinir | 100 mg PO 8 hourly | |
| Cefditoren pivoxil | 200 mg PO 12 hourly x 10 days | |
| Cefoperazone | 2-4 g/day IV/IM divided hourly | |
| Cefotaxime | 1-2 g IV/IM 12 hourly | |
| Ceftazidime | 1-2 g IV/IM 8 hourly | |
| Ceftriaxone | 1-2 g IV/IM 12-24 hourly | |
| Fourth Generation | ||
| Cefepime | 1-2 g IV/IM 12 hourly | |
| Cefpirome | 1 g IV/IM 12 hourly | |
| Fifth Generation | ||
| Ceftaroline fosamil |
Minimum inhibitory concentration (MIC) <2 mg/L: 600 mg IV infusion over 5-60 minutes 12 hourly MIC 2-4 mg/L: 600 mg IV infusion over 120 minutes 8 hourly |
|
| Cephalosporin with Beta-lactamase Inhibitor | ||
| Cefoperazone/sulbactam | 2-4 g IV/IM 12 hourly May be increased to 8 g/day IV 12 hourly for severe infections |
|
Macrolides
| Drug | Dosage | Remarks |
|---|---|---|
| Azithromycin |
500 mg PO 24 hourly x 3 days or 500 mg PO 24 hourly x 1 day followed by 250 mg PO 24 hourly x 4 days |
Adverse Reactions
|
| Clarithromycin |
250-500 mg PO 12 hourly Extended-release: 500 mg-1 g PO 24 hourly or 500 mg IV 12 hourly x 2-5 days, then switch to oral therapy |
|
| Erythromycin |
500 mg PO 6 hourly or 25-50 mg/kg/day IV in divided doses Max dose: 4 g/day |
|
| Roxithromycin |
150 mg PO 12 hourly or 300 mg PO 24 hourly x 5-10 days |
Other Antibiotics
| Drug | Dosage | Remarks |
|---|---|---|
| Clindamycin | 300-450 mg PO 6 hourly or 600 mg IV/IM 8 hourly or 900 mg IV 8 hourly |
Adverse Reactions
|
| Daptomycin | 4 mg/kg IV 24 hourly |
Adverse Reactions
|
| Lincomycin | 500 mg PO 8 hourly or 600 mg IM 12-24 hourly or 600-1,000 mg IV 8-12 hourly |
Adverse Reactions
|
| Linezolid | 400-600 mg PO/IV 12 hourly |
Adverse Reactions
|
| Metronidazole |
Pelvic cellulitis: 1 g vaginal suppository 8 hourly Treatment of ≥3 days: 1 g vaginal suppository 12 hourly |
Adverse Reactions
|
| Sodium fusidate | 250 mg PO 12 hourly |
Adverse Reactions
|
| Teicoplanin |
Initial dose: 6 mg/kg IM/IV bolus over 3-5 minutes or infused over 30 minutes 12 hourly x 3 doses Maintenance dose: 6 mg/kg IM/IV 24 hourly |
Adverse Reactions
|
| Vancomycin |
500 mg IV 6 hourly or 1 g IV 12 hourly |
Adverse Reactions
|
Other Beta-lactams
| Drug | Dosage | Remarks |
|---|---|---|
| Carbapenems | ||
| Imipenem/cilastatin | 500 mg IV 6 hourly or 1 g IV 8 hourly |
Adverse Reactions
|
| Meropenem | 500-1,000 mg IV 8 hourly | |
| Monobactam | ||
| Aztreonam | 1-2 g IV 8-12 hourly | Adverse Reactions
|
Penicillins
| Drug | Dosage | Remarks |
|---|---|---|
| Benzylpenicillin (Penicillin G, Penicillin G Na, Penicillin G K) | 0.6-2.4 g IM/IV/day divided 6-12 hourly |
Adverse Reactions
|
|
Phenoxymethylpenicillin (Penicillin V) |
250-500 mg PO 4-6 hourly | |
| Aminopenicillins with or without Beta-lactamase Inhibitors | ||
| Amoxicillin (Amoxycillin) |
250-500 mg PO 8 hourly or 500 mg PO 12 hourly |
|
|
Amoxicillin/clavulanic acid (Co-amoxiclav, Amoxicillin/clavulanate) |
375 mg PO 8 hourly or 625 mg PO 8-12 hourly or 1 g PO 8-12 hourly or 1.2 g IV 6-8 hourly |
|
|
Ampicillin/sulbactam (Sultamicillin: Pro-drug of Ampicillin/sulbactam) |
1.5-3 g IV 6 hourly | |
|
Sultamicillin tosylate (Sultamicillin tosilate) |
375-750 mg PO 12 hourly | |
|
Antipseudomonal Penicillins with or without Beta-lactamase Inhibitors |
||
| Piperacillin |
3-4 g IV/IM 4-6 hourly Max dose: 24 g/day |
|
| Piperacillin/tazobactam | 2.25-4.5 g IV/IM 6-8 hourly | |
| Ticarcillin | 200-300 mg/kg/day IV divided 4-6 hourly | |
|
Ticarcillin/clavulanic acid (Ticarcillin/clavulanate) |
3.2 g IV 6-8 hourly | |
| Antistaphylococcal Penicillins | ||
| Cloxacillin |
250-500 mg PO 6 hourly Max dose: 6 g/day or 250-500 mg IM/IV 4-6 hourly |
|
| Dicloxacillin | 125-500 mg PO 6 hourly | |
| Flucloxacillin |
250-500 mg PO 6 hourly or 250-500 mg IM 6 hourly or 250 mg-1 g IV 6 hourly |
|
| Oxacillin |
500 mg-1 g PO 6 hourly Max dose: 12 g/day or 250 mg-2 g IV/IM 4-6 hourly |
|
Quinolones
| Drug | Dosage | Remarks |
|---|---|---|
| Ciprofloxacin | 500-750 mg PO 12 hourly or 400 mg IV 8-12 hourly infused over 30-60 minutes |
Adverse Reactions
|
| Delafloxacin | 450 mg PO 12 hourly or 300 mg IV infusion over 60 minutes 12 hourly |
|
| Levofloxacin | 500-750 mg PO/IV 24 hourly | |
| Moxifloxacin | 400 mg PO/IV 24 hourly | |
| Ofloxacin | 400 mg PO/IV 12 hourly |
Tetracyclines
| Drug | Dosage | Remarks |
|---|---|---|
| Doxycycline | 100 mg PO 12 hourly or 200 mg PO 24 hourly x 1 day Followed by 50 mg PO 12 hourly or 100 mg PO 24 hourly |
Adverse Reactions
|
| Minocycline | 100-200 mg PO 24 hourly x 1 day Followed by 100 mg PO 12 hourly |
|
| Tigecycline | 100 mg IV 24 hourly as loading dose Followed by 50 mg IV 12 hourly |
Topical Antibiotic
| Drug | Dosage | Remarks |
|---|---|---|
| Mupirocin | Apply to affected area 8-12 hourly x 10 days | Adverse Reactions
|
Disclaimer
All dosage recommendations are for non-pregnant and non-breastfeeding women, and non-elderly adults with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
